FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2936974622> ?p ?o ?g. }

• W2936974622 endingPage "296.e4" @default.
• W2936974622 startingPage "287" @default.
• W2936974622 abstract "BackgroundThe real-world effect of anti-programmed death ligand 1 (PD-L1) therapies is unclear. We compared US patients who received second-line therapy for non–small-cell lung cancer (NSCLC) before and shortly after US Food and Drug Administration (FDA) approval of PD-L1 inhibitors.Patients and MethodsPatients in the Flatiron Health database (≥18 years; received first-line platinum therapy for advanced/metastatic NSCLC; ≥6 months of follow-up) were assessed before (“historical”: January 1, 2011 to December 31, 2013) and after (“current”: January 1, 2015 to May 31, 2017) FDA approval of anti–PD-L1 therapies for NSCLC. Index was start of second-line therapy. Baseline variables, treatment patterns, and overall survival (OS) were reported.ResultsA greater proportion of patients in the current cohort received second-line treatment than in the historical cohort (n = 4240 [57.0%] vs. n = 2357 [37.4%]); 48.8% [n = 2071] of the current second-line patients received anti–PD-L1 therapy. Current patients were more likely to receive second-line anti–PD-L1 therapy if they had poorer Eastern Cooperative Oncology Group (ECOG) performance status (≥2), had squamous histology, or had no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS proto-oncogene 1 mutations. Median OS from index was higher in the current cohort (9.4 [95% confidence interval (CI), 8.9-9.9] months) than the historical cohort (7.3 [95% CI, 6.9-7.8] months). Adjusted for sex, race, ECOG performance status, disease stage, and Kirsten rat sarcoma viral oncogene homolog, EGFR, and ALK status, OS was improved by 15% in the current cohort.ConclusionContemporary patients are more likely to receive second-line therapy and have longer OS than patients who received care before approval of anti–PD-L1 therapies." @default.
• W2936974622 created "2019-04-25" @default.
• W2936974622 creator A5013163191 @default.
• W2936974622 creator A5014374360 @default.
• W2936974622 creator A5042973046 @default.
• W2936974622 creator A5050489521 @default.
• W2936974622 creator A5064227174 @default.
• W2936974622 creator A5072563567 @default.
• W2936974622 creator A5075978838 @default.
• W2936974622 date "2019-07-01" @default.
• W2936974622 modified "2023-09-24" @default.
• W2936974622 title "Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non–Small Cell Lung Cancer After Platinum Chemotherapy" @default.
• W2936974622 cites W1540531200 @default.
• W2936974622 cites W1977749101 @default.
• W2936974622 cites W2010211751 @default.
• W2936974622 cites W2077633559 @default.
• W2936974622 cites W2091418343 @default.
• W2936974622 cites W2104347254 @default.
• W2936974622 cites W2143330591 @default.
• W2936974622 cites W2151799520 @default.
• W2936974622 cites W2156353875 @default.
• W2936974622 cites W2163275813 @default.
• W2936974622 cites W2198093519 @default.
• W2936974622 cites W2296023454 @default.
• W2936974622 cites W2301488980 @default.
• W2936974622 cites W2346719010 @default.
• W2936974622 cites W2368001341 @default.
• W2936974622 cites W2561345138 @default.
• W2936974622 cites W2567564314 @default.
• W2936974622 cites W2588675203 @default.
• W2936974622 cites W2658569466 @default.
• W2936974622 cites W2762777471 @default.
• W2936974622 cites W2781525129 @default.
• W2936974622 cites W2783592711 @default.
• W2936974622 cites W2790743957 @default.
• W2936974622 cites W2791043965 @default.
• W2936974622 cites W2802509580 @default.
• W2936974622 cites W2811161985 @default.
• W2936974622 cites W2891812963 @default.
• W2936974622 cites W2905538776 @default.
• W2936974622 cites W2910245285 @default.
• W2936974622 cites W2990271277 @default.
• W2936974622 doi "https://doi.org/10.1016/j.cllc.2019.04.004" @default.
• W2936974622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31130450" @default.
• W2936974622 hasPublicationYear "2019" @default.
• W2936974622 type Work @default.
• W2936974622 sameAs 2936974622 @default.
• W2936974622 citedByCount "26" @default.
• W2936974622 countsByYear W29369746222019 @default.
• W2936974622 countsByYear W29369746222020 @default.
• W2936974622 countsByYear W29369746222021 @default.
• W2936974622 countsByYear W29369746222022 @default.
• W2936974622 countsByYear W29369746222023 @default.
• W2936974622 crossrefType "journal-article" @default.
• W2936974622 hasAuthorship W2936974622A5013163191 @default.
• W2936974622 hasAuthorship W2936974622A5014374360 @default.
• W2936974622 hasAuthorship W2936974622A5042973046 @default.
• W2936974622 hasAuthorship W2936974622A5050489521 @default.
• W2936974622 hasAuthorship W2936974622A5064227174 @default.
• W2936974622 hasAuthorship W2936974622A5072563567 @default.
• W2936974622 hasAuthorship W2936974622A5075978838 @default.
• W2936974622 hasBestOaLocation W29369746221 @default.
• W2936974622 hasConcept C117643217 @default.
• W2936974622 hasConcept C121608353 @default.
• W2936974622 hasConcept C126322002 @default.
• W2936974622 hasConcept C143998085 @default.
• W2936974622 hasConcept C2776232967 @default.
• W2936974622 hasConcept C2776256026 @default.
• W2936974622 hasConcept C2776694085 @default.
• W2936974622 hasConcept C2776907518 @default.
• W2936974622 hasConcept C2778239845 @default.
• W2936974622 hasConcept C2780350996 @default.
• W2936974622 hasConcept C2781230642 @default.
• W2936974622 hasConcept C71924100 @default.
• W2936974622 hasConcept C72563966 @default.
• W2936974622 hasConceptScore W2936974622C117643217 @default.
• W2936974622 hasConceptScore W2936974622C121608353 @default.
• W2936974622 hasConceptScore W2936974622C126322002 @default.
• W2936974622 hasConceptScore W2936974622C143998085 @default.
• W2936974622 hasConceptScore W2936974622C2776232967 @default.
• W2936974622 hasConceptScore W2936974622C2776256026 @default.
• W2936974622 hasConceptScore W2936974622C2776694085 @default.
• W2936974622 hasConceptScore W2936974622C2776907518 @default.
• W2936974622 hasConceptScore W2936974622C2778239845 @default.
• W2936974622 hasConceptScore W2936974622C2780350996 @default.
• W2936974622 hasConceptScore W2936974622C2781230642 @default.
• W2936974622 hasConceptScore W2936974622C71924100 @default.
• W2936974622 hasConceptScore W2936974622C72563966 @default.
• W2936974622 hasFunder F4320307115 @default.
• W2936974622 hasIssue "4" @default.
• W2936974622 hasLocation W29369746221 @default.
• W2936974622 hasLocation W29369746222 @default.
• W2936974622 hasOpenAccess W2936974622 @default.
• W2936974622 hasPrimaryLocation W29369746221 @default.
• W2936974622 hasRelatedWork W1591408781 @default.
• W2936974622 hasRelatedWork W2097791366 @default.
• W2936974622 hasRelatedWork W2098897002 @default.
• W2936974622 hasRelatedWork W2137737798 @default.

• next